Abstract: Poster Presentations |

Novel streptokinase nanodevices for enhanced thrombolysis: Preparation, in vitro and in vivo studies FREE TO VIEW

Sujatha Kannan, MD*; Omathanu P. Perumal, PhD; Rangaramanujam M. Kannan, PhD; Rajyalakshmi I; Jayant Khandare, PhD; Mary Lieh-Lai, MD
Author and Funding Information

Children’s Hospital of Michigan/Wayne State University, Detroit, MI


Chest. 2004;126(4_MeetingAbstracts):878S. doi:10.1378/chest.126.4_MeetingAbstracts.878S-a
Text Size: A A A
Published online


PURPOSE:  Venous thromboemboli constitute an increasing problem in children with complex medical problems. The treatment of thromboemboli in children is challenging because unlike in adults, the use of thrombolytics is not well studied and is often associated with bleeding. These risks can be minimized by delivering the thrombolytic agent specifically and directly to the clot. Our objective is to use novel dendritic nanodevices loaded with streptokinase (SK) to achieve enhanced clot lysis. We hypothesize that these nanodevices enhance clot lysis by improving the stability of streptokinase, decreasing its immunogenicity and allowing more effective diffusion of the nanodevice into the clot to deliver the drug.

METHODS:  Three different nanodevices were designed: Hydroxyl terminated nanopolymers that were (1)complexed with SK and (2)conjugated with SK and (3)polylactic acid-glycolic acid nanoparticles loaded with SK. Drug loading was determined by Lowry protein estimation, and streptokinase activity evaluated using a chromogenic assay kit. A rabbit model of jugular venous thrombus using time, extent of reperfusion (measured by doppler flowmetry) and decrease in clot weight as therapeutic end points was established for in vivo testing of nanodevices.

RESULTS:  In vitro studies showed that streptokinase was present in the nanodevices. Streptokinase activity was measured using a chromogenic assay and it was found to be active. From kinetic analysis, it was found that the streptokinase nanodevices took a longer time than free streptokinase to hydrolyse the peptide substrate nanoparticle>conjugate>complex>free SK. In vivo studies, showed that treatment with saline did not produce any significant reperfusion. Upon treatment with free streptokinase 30% of baseline blood flow was restored in 60 minutes. The clot weight with streptokinase treatment was 60% of control.

CONCLUSION:  These results indicate that novel streptokinase loaded nanodevices can be successfully prepared and that they achieve sustained and controlled delivery of streptokinase. The in vivo model has been established and the nanodevices will be tested.

CLINICAL IMPLICATIONS:  Nanodevices can non-invasively enhance clot lysis and minimize side effects by achieving controlled delivery of thrombolytics.

DISCLOSURE:  S. Kannan, None.

Wednesday, October 27, 2004

12:30 PM- 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
Acute ST-Segment Elevation Myocardial Infarction*: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543